92 related articles for article (PubMed ID: 1586379)
1. Antiplatelet effects of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in relation to its disposition in rats, rabbits and dogs.
Ohmuro S; Sasahara T; Taga F; Ohkubo H; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):43-7. PubMed ID: 1586379
[TBL] [Abstract][Full Text] [Related]
2. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals.
Momo K; Someya K; Tachiiri T; Mitsuoka Y; Nakamura K; Imai S; Ino T; Ohkubo H
Arzneimittelforschung; 1992 Jan; 42(1):32-9. PubMed ID: 1586377
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit.
Ohmuro S; Tsukada Y; Taga F; Ohkubo H; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):39-42. PubMed ID: 1586378
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in laboratory animals.
Komuro M; Hori W; Hotta M; Saitoh S; Ishida R; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):55-9. PubMed ID: 1586381
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent].
Yoshioka M; Soga T; Mase K; Yasunaga K
Nihon Rinsho; 1992 Feb; 50(2):379-84. PubMed ID: 1613994
[TBL] [Abstract][Full Text] [Related]
6. Identification of urinary metabolites of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in rat, rabbit and dog.
Komuro M; Ishida R; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):48-55. PubMed ID: 1586380
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
Terashita Z; Imura Y; Nishikawa K
J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in human subjects.
Nakashima M; Kanamaru M; Uematsu T; Mizuno A; Toriumi C; Hotta M; Komuro M; Ishida R; Uchida H
Arzneimittelforschung; 1992 Jan; 42(1):60-4. PubMed ID: 1586382
[TBL] [Abstract][Full Text] [Related]
10. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
11. I4, a new synthetic sulfonylurea compound, inhibits the action of TXA2 in vivo and in vitro on platelets and aorta vascular smooth muscle.
Lu N; Zhan M; Gao C; Wu G; Zhang H
Thromb Res; 2012 Oct; 130(4):e209-15. PubMed ID: 22909828
[TBL] [Abstract][Full Text] [Related]
12. A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation.
Ohashi M; Ohkubo H; Kito J; Nishino K
Arch Int Pharmacodyn Ther; 1986 Oct; 283(2):321-34. PubMed ID: 3024600
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of arterial PGI2 generation and platelet aggregation by aspirin in rabbits ex vivo.
Basista M
Pol J Pharmacol Pharm; 1982; 34(5-6):317-21. PubMed ID: 6821216
[TBL] [Abstract][Full Text] [Related]
14. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
15. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
Karasawa A; Shirakura S; Higo K; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
[TBL] [Abstract][Full Text] [Related]
16. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
17. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid.
Minuz P; Lechi C; Tommasoli R; Gaino S; Degan M; Zuliani V; Bonapace S; Benoni G; Adami A; Cuzzolin L
Thromb Res; 1995 Dec; 80(5):367-76. PubMed ID: 8588198
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
19. Various laboratory protocols for measuring thromboxane A2 generation to detect the effectiveness of acetylsalicylic acid therapy: a comparative study.
Rozalski M; Watala C; Golanski J
Blood Coagul Fibrinolysis; 2014 Jan; 25(1):46-51. PubMed ID: 24365771
[TBL] [Abstract][Full Text] [Related]
20. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species.
Nishio S; Matsuura H; Kanai N; Fukatsu Y; Hirano T; Nishikawa N; Kameoka K; Umetsu T
Jpn J Pharmacol; 1988 May; 47(1):1-10. PubMed ID: 2842529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
